Literature DB >> 11081597

Tumor growth and audiometric change in vestibular schwannomas managed conservatively.

D D Massick1, D B Welling, E E Dodson, M Scholfield, H N Nagaraja, P Schmalbrock, D W Chakeres.   

Abstract

OBJECTIVE: To prospectively define the correlation between changes in tumor volume and audiometric function in vestibular schwannomas managed conservatively. STUDY
DESIGN: Prospective longitudinal study.
METHODS: Twenty-one patients (age range, 15-84 y; mean age, 63.3 y) with newly diagnosed vestibular schwannomas were enrolled between 1994 and 1999 in a protocol at The Ohio State University Hospital (Columbus, OH) to evaluate the correlation between tumor volume and audiometric change during a period of observation. Patients were evaluated yearly by clinical examination, a standardized internal auditory canal magnetic resonance imaging scan with gadolinium contrast for volumetric analysis, and audiometric function testing. Demographic data, historical features, neurofibromatosis type 2 (NF2) status, initial testing results, and serial testing results were recorded.
RESULTS: An increase in tumor volume occurred in 14 of the 21 patients (66%). The pattern of volumetric change was found to be extremely variable. Multiple regression analysis revealed significant correlations of changes in tumor volume with changes in pure-tone average and speech discrimination score (P < .0001 and P = .0021, respectively). Change in tumor volume had greater effect on pure-tone average and speech discrimination score in patients initially with class D audiometric function when compared with those initially in class A (P = .0083 and P = .0245, respectively). The presence of NF2 had an independent protective effect against deterioration of the pure-tone average when compared with patients without NF2 (P = .0125).
CONCLUSIONS: This study demonstrated a significant correlation between a change in volume and auditory deterioration in vestibular schwannomas being managed with a trial of observation. A given change in tumor volume appeared to have a greater effect on pure-tone average and speech discrimination score as initial auditory classification declined.

Entities:  

Mesh:

Year:  2000        PMID: 11081597     DOI: 10.1097/00005537-200011000-00015

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  13 in total

1.  Outcome on hearing and facial nerve function in microsurgical treatment of small vestibular schwannoma via the middle cranial fossa approach.

Authors:  Christian Ginzkey; Matthias Scheich; Wilma Harnisch; Verena Bonn; Desiree Ehrmann-Müller; Wafaa Shehata-Dieler; Robert Mlynski; Rudolf Hagen
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-06-22       Impact factor: 2.503

2.  The natural history of vestibular schwannoma growth-prospective 40-year data from an unselected national cohort.

Authors:  Martin Reznitsky; Mette Marie Babiel Schmidt Petersen; Niels West; Sven-Eric Stangerup; Per Cayé-Thomasen
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

3.  Progress of hearing loss in neurofibromatosis type 2: implications for future management.

Authors:  Georgios Kontorinis; Jaya Nichani; Simon R Freeman; Scott A Rutherford; Samantha Mills; Andrew T King; Deborah Mawman; Sue Huson; Martin O'Driscoll; D Gareth Evans; Simon K W Lloyd
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-08       Impact factor: 2.503

4.  Long-term outcomes of vestibular schwannomas treated with fractionated stereotactic radiotherapy: an institutional experience.

Authors:  Sumit Kapoor; Sachin Batra; Kathryn Carson; John Shuck; Siddharth Kharkar; Rahul Gandhi; Juan Jackson; Jan Wemmer; Stephanie Terezakis; Ori Shokek; Lawrence Kleinberg; Daniele Rigamonti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-29       Impact factor: 7.038

5.  Single Institutional Experience With Observing 564 Vestibular Schwannomas: Factors Associated With Tumor Growth.

Authors:  Jacob B Hunter; David O Francis; Brendan P O'Connell; Edmond K Kabagambe; Marc L Bennett; George B Wanna; Alejandro Rivas; Reid C Thompson; David S Haynes
Journal:  Otol Neurotol       Date:  2016-12       Impact factor: 2.311

6.  Preoperative audiovestibular handicap in patients with vestibular schwannoma.

Authors:  Rachel L Humphriss; David M Baguley; Patrick R Axon; David A Moffat
Journal:  Skull Base       Date:  2006-11

7.  Predictors of future growth of sporadic vestibular schwannomas obtained by history and radiologic assessment of the tumor.

Authors:  Janneke C J M Artz; Ferdinand C A Timmer; Jef J S Mulder; Cor W R J Cremers; Kees Graamans
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-08-13       Impact factor: 2.503

8.  Change in hearing and tinnitus in conservatively managed vestibular schwannomas.

Authors:  Nicola Quaranta; David M Baguley; David A Moffat
Journal:  Skull Base       Date:  2007-07

Review 9.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

10.  Hearing improvement in a growing vestibular schwannoma.

Authors:  Marcos Martinez Del Pero; Simon K W Lloyd; David A Moffat
Journal:  Skull Base       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.